Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: [email protected]
 

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

Principal Investigator: Kabraji, Sheheryar K

A Phase 1 Study of ASCIMINIB in combination with dasatinib, prednisone, and blinatumomab in patients with BCR-ABL1 positive (BCR-ABL1+) B-cell acute lymphoblastic leukemia (B-ALL) and chronic myeloid leukemia (CML)

Principal Investigator: Wang, Eunice S

NRG-GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based…

Principal Investigator: Zsiros, Emese

A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide,…

Principal Investigator: Hillengass, Jens

A phase 1b dose optimization study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serous ovarian cancer

Principal Investigator: McLean, Karen

Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients

Principal Investigator: Zsiros, Emese

(ACNS2031) A Phase 3 Study of Sodium Thiosulfate for the Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy for Children with Medulloblastoma with Low-Risk Features

Principal Investigator: Twist, Clare J

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Principal Investigator: Thompson, J

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Principal Investigator: Fountzilas, Christos

A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma

Principal Investigator: Fountzilas, Christos

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

Principal Investigator: Niu, Alex

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

Principal Investigator: Wang, Eunice S

HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors

Principal Investigator: Fountzilas, Christos

B-Adrenergic Blockade with Chemotherapy and Checkpoint Inhibition in PD-L1
Positive Metastatic Triple Negative Breast Cancer

Principal Investigator: Kabraji, Sheheryar K

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Principal Investigator: Cortese, Matthew J

A scalable cruciferous vegetable intervention to reduce bladder cancer recurrence and progression

Principal Investigator: Yeary, Karen H

(A012301) LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer

Principal Investigator: Levine, Ellis G

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients with Relapsed or Refractory Multiple Myeloma (MM) with Extramedullary Disease (EMD)

Principal Investigator: Hillengass, Jens

(AREN1921) Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Principal Investigator: Twist, Clare J

Randomized Phase 2 Study: Neoadjuvant conditioning of prostate cancer tumor microenvironment using a novel chemokine-modulating regimen

Principal Investigator: Chatta, Gurkamal S

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic…

Principal Investigator: Thompson, J

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Principal Investigator: Mager, Katherine

A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Principal Investigator: Malek, Ehsan

A Phase 1, First-in-Human, Open-Label, DoseEscalation and Expansion Study of IMGN151 (anti-FR-alpha antibody drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers

Principal Investigator: Zsiros, Emese